Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HL217 Eye Drops in Healthy Males
NCT03648346Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KR-31831 in age-related macular degeneration (AMD) (3 arms), sponsored by Hanlim Pharm. Primary endpoints: Adverse Events, Physical Examination and 4 more. Started Apr 2018; status: completed.
02
Drugs
KR-31831
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT03648346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03648346.